MissionIR Small-Cap Investor Blog: February 2020

Friday, February 28, 2020

MissionIRNewsBreaks – Youngevity International, Inc.’s (NASDAQ: YGYI) Khrysos Industries Hosts First HIAF Educational Event of 2020 at its Orlando-Based Headquarters

Youngevity International (NASDAQ: YGYI) together with its subsidiary and hemp enterprise, Khrysos Industries, Inc., today announced that Khrysos, on Thursday, hosted the first educational and networking event of 2020 for the Hemp Industry Association of Florida (“HIAF”) at its Orlando-based headquarters. According to the update, industry leaders from Florida’s hemp sector and other HIAF board members were treated to a “Hemp Extraction Lab Tour & Workshop” at Khrysos Industries, which operates the largest processing facility in Florida. HIAF, state and federal regulatory updates were also provided during the event. “It was a high honor to host the first HIAF educational event of 2020 and to have the chance to share our vision and capabilities with Florida’s leaders in the Hemp Industry,” YGYI President and CFO Dave Briskie said in the news release. “Dwayne Dundore gave a fantastic presentation and a large group of influencers learned all about Khrysos Industries and its significant capabilities.”

To view the full press release, visit http://ibn.fm/PTTC2

About Youngevity International, Inc.

YGYI, Inc. (NASDAQ: YGYI), is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model, that also offers e-commerce and the power of social selling. Assembling a virtual Main Street of products and services under one corporate entity, YGYI offers products from the eight top-selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, fashion, essential oils, photo, as well as innovative services. The company was formed in the course of the summer 2011 merger of Youngevity Essential Life Sciences with Javalution(R) Coffee company (now part of the company’s food and beverage division). The resulting company became Youngevity International, Inc. in July 2013. For investor information, please visit www.YGYI.com.

NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://ibn.fm/YGYI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Trxade Group, Inc. (NASDAQ: MEDS) CEO Rings Nasdaq Opening Bell

Trxade Group (NASDAQ: MEDS) announced that the company’s chief executive officer Suren Ajjarapu will ring the Nasdaq opening bell at 9:30 AM ET on February 28, 2020, signifying the start of trade. Trxade Group is an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals. The company’s common stock began trading on the Nasdaq Capital Market under its new symbol ‘MEDS’ on February 13, 2020.

To view the full press release, visit http://ibn.fm/fCKGu

About Trxade Group, Inc.

Headquartered in Tampa, Florida, Trxade Group, Inc. (NASDAQ: MEDS) is an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms; the Trxade B2B trading platform with 11,900 registered pharmacies, licensed virtual Wholesale and Mail Order Pharmacy delivery capabilities using DelivMeds app. For additional information, please visit www.Trxade.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Thursday, February 27, 2020

MissionIRNewsBreaks – Jerrick Media Holdings Inc. (JMDA) Offers Creators Opportunity to Win Prizes, Enjoy Experiences via Vocal Platform Challenges

Jerrick Media Holdings (OTCQB: JMDA), a holding company that gives technology products the resources and opportunities to make ideas a reality, recently announced its newest revenue-generating feature on its Vocal platform, Challenges. An article discussing the company reads, “Vocal’s first-month Challenge themes include Mobile Moments, a partner Challenge with a company called Moment that invites creators to share a favorite smartphone photo along with the story behind it; Locals Only, a Challenge encouraging creators to show off hidden spots in their hometowns; and Behind the Beat, a music-focused contest exclusive to Vocal+ members that looks at the songs that have changed creators’ lives. Complete information about the Challenges can be found at http://ibn.fm/onEFg. . . . ‘Challenges are the most important product update introduced into Vocal to date, allowing creators to connect with brands in an authentic, noninterruptive way that builds brand love and affinity while simultaneously giving creators more of what they love about Vocal–monetization and discovery,’ said Jerrick president and Vocal founder Justin Maury.”

To view the full article, visit http://ibn.fm/xw1x9

About Jerrick

Jerrick is a holding company that develops technology-based solutions. Its flagship product — Vocal — is a long-form, digital-publishing platform focused on supporting content creators by providing them with publishing tools and monetization features that are embedded within digital communities. Vocal is architected to enable targeted marketing of branded content and e-commerce opportunities embedded within long-form content. Vocal’s community sites are managed by a dedicated team, whose primary focus is on creating safe communities and identifying monetization opportunities within those communities. For more information, visit the company’s website at https://Jerrick.media.

NOTE TO INVESTORS: The latest news and updates relating to JMDA are available in the

company’s newsroom at http://ibn.fm/JMDA

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

MissionIRNewsBreaks – Sigma Labs, Inc. (NASDAQ: SGLB) to Effect Reverse Stock Split to Regain Compliance with Nasdaq Listing Rule

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, today announced that it will effect a one-for-ten reverse stock split of its outstanding common stock to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq Listing Rule 5550(a)(2). According to the update, Sigma’s common stock will begin trading on the Nasdaq Capital Market on a split adjusted basis at market open on Friday, February 28, 2020, and will continue to trade under the “SGLB” symbol. Following the reverse stock split, the new CUSIP number for the common stock will be 826598500. The number of common stock shares that Sigma Labs is authorized to issue will correspondingly decrease from 22,500,000 to 2,250,000 shares.

To view the full press release, visit http://ibn.fm/LdLm1

About Sigma Labs

Sigma Labs, Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D(R) brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (“CAI”) solutions known as PrintRite3D(R) for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

MissionIRNewsBreaks – Youngevity International, Inc.’s (NASDAQ: YGYI) Khrysos Industries Secures $1.5M Equipment Deal

Youngevity International (NASDAQ: YGYI), a multi-channel lifestyle company operating in three distinct business segments, together with its subsidiary and hemp enterprise, Khrysos Industries, Inc., today announced that its equipment division completed the sale of a $1.5 million extraction and distillation system along with other related equipment to a customer located in the central part of the U.S. According to the update, the fully built system is scheduled to ship before the end of the month. “We are excited to place two of our state-of-the-art CO2 extraction systems, and other hemp processing systems with a new account located in the Midwest,” Khrysos President Dwayne Dundore, PhD, said in the news release. “We are encouraged to see smart customers looking for more efficient and cost-effective systems like we offer at Khrysos.”

To view the full press release, visit http://ibn.fm/MN9Gb

About Youngevity International, Inc.

NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://ibn.fm/YGYI

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Sigma Labs Inc. (NASDAQ: SGLB) Positioned to Leverage Opportunities in Aviation Industry with In-Process QC Software for 3D Metal Parts

3D metal printing for aviation industry forecast to surge into serial production in this decade
SGLB is only provider of in-process, quality-assurance software that offers in-process solutions to primary industry roadblocks
3D printing is increasingly adopted at all levels of aviation industry through pressure by tier-1 suppliers such as GE Aviation, Rolls Royce and Honeywell

Opportunities in 3D metal printing for the aviation space are forecast to exceed $7 billion within the next decade (http://ibn.fm/4hVsi) as the industry moves past the prototype phase and scales to its full profit potential. Sigma Labs Inc. (NASDAQ: SGLB) is the only provider of quality-assurance software that aims to remove remaining impediments to profitability by solving in-process, quality-control issues.

Also referred to as additive manufacturing, the 3D metal printing process produces three-dimensional objects by sintering metals layer by layer through the use of computer-aided design (CAD) files. Variances in the additive manufacturing process prevent consistent quality and often result in rejected output during post-production inspections. Through its PrintRite3D(R) brand, SGLB is positioning itself as the go-to provider of solutions that promise to eliminate inefficiencies, save time and allow the industry to profitably scale.

Driven by large aviation-parts players such GE Aviation, Rolls Royce and Honeywell, the use of additive manufacturing is increasingly being adopted at all levels of the industry through pressure by these tier-1 suppliers. As more companies seek to leverage this opportunity, demand for innovative solutions promising to save time, refine the production process and prevent rejected output continues to increase.

As the sole provider of quality-control solutions, SGLB provides software that addresses these critical issues in two ways: first, by enabling real-time, in-process detection of manufacturing irregularities, and second, through the provision of error reporting that provides operators with critical, actionable information that enables them to address any developing anomalies during the production process. Since manufacturers currently cannot tell if design specifications are met until the end of the production process, SGLB’s software potentially reduces the rejected output and postproduction inspection times by allowing operators to monitor manufacturing in real time.

Founded by a team of Los Alamos National Labs scientists and engineers in 2010, Sigma Labs first operated as a developer of commercially licensed, advanced metallurgical products before entering the 3D-metal-printing space. Forecasting high demand for quality-control solutions in this area, the company has since focused on creating products and services geared toward highly demanding, precision-dependent companies in the aerospace, defense, transportation, oil and gas, and biomedical industries.

SGLB’s global client base includes many tier-1 OEM enterprises and end users, including Airbus, Baker Hughes and Pratt & Whitney. With current 3D metal industry annual revenues estimated at more than $1.4 billion, the addition of quality-assurance software to the commercial 3D-metal-printing industry is expected to help the industry toward its forecast growth to $3.9 billion by 2023. Referred to by many as the fourth industrial revolution, additive manufacturing has tremendous potential, assuming a primary impediment for scaling and profitability – quality control – can be overcome. SGLB is positioning itself as the premier provider of innovative software solutions that address this demand.

For more information about Sigma Labs, please visit www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

MissionIRNewsBreaks – Pressure BioSciences, Inc. (PBIO) Announces Official Opening of its Ultra Shear Technology(TM) Demonstration Laboratory

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics and other industries, today announced the official opening of its new Ultra Shear Technology(TM) (“UST”) Demonstration Laboratory. According to the update, the major purpose of the UST Demo Lab, located in the company’s South Easton, Massachusetts facility, is to showcase the ability of the company’s revolutionary UST Platform to process CBD oil into true, high quality, water-soluble nanoemulsions. A second purpose is to invite potential purchasers of Pressure BioSciences’ UST-based BaroShear Systems (initial release expected Q4 2020) to evaluate how their CBD and other product formulations work with the company’s revolutionary UST platform. “The initial reactions from manufacturers of topical and ingestible cannabidiol products processed in our lab during the trial period have been extremely positive. They quickly saw how they could realize substantial cost reductions while eliminating the overloading of poorly water-soluble CBD and other cannabinoids into products to achieve targeted dosing levels,” PBIO President and CEO Richard T. Schumacher said in the news release. “We believe our breakthrough technology platform provides them with a new-found ability to provide safe and effective dosing for their customers, which in turn should stimulate greater growth in the market for CBD-based products overall, and strong sales of our BaroShear product line when it is released to the market later this year.”

To view the full press release, visit http://ibn.fm/6lLD6

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Trxade Group Inc. (NASDAQ: MEDS) to Celebrate Nasdaq Uplisting with Opening Bell on Friday

Pharmaceutical services business Trxade Group Inc. recently announced its uplisting to the Nasdaq Capital Market and will ring the exchange’s opening bell this Friday, February 28, 2020
The ringing of the opening bell will be broadcast live at 9:30 a.m. EST from the Nasdaq’s Times Square market site in New York City
The company will cease trading on the OTC market and phase out its ‘TRXD’ ticker as part of the move, transitioning to new Nasdaq ticker ‘MEDS’
Trxade Group is a pioneer in building a supplier-to-pharmacy platform that helps small, independent businesses be competitive with larger chains by sourcing drugs at discount prices, building consumer confidence through transparency in operations
The company’s network of pharmaceutical partners continues to expand, aiming to eventually reach most, if not all, of the nation’s 24,000 independent pharmacies

Pharmacy services B2B innovator Trxade Group Inc. (NASDAQ: MEDS) will ring the Nasdaq opening bell Friday, February 28, to celebrate the supplier-to-pharmacy business’s uplisting to the Capital Market exchange, which the company announced February 13.

As one circumstance of the move, Trxade will begin trading under the ticker MEDS and will phase out its previously existing OTC common stock symbol, ‘TRXD’. The iconic ringing of the bell represents a significant milestone for companies and an opportunity for them to celebrate their achievements in front of a global audience. The bell ringing will be broadcast live via satellite at 9:30 a.m. from the Nasdaq’s Time Square market site in New York City, following an hour of lead-up promotional events with Nasdaq senior executives.

“We’ve been under the radar for a long time. We’re trying to create visibility among the investor base by doing the right thing,” CEO Suren Ajjarapu stated late last year following completion of an agreement between its subsidiary Bonum Health and Benzer Pharmacy to create a network of ‘Bonum Health Hub’ units in small towns and rural areas as part of the lead-up to the Nasdaq listing (http://ibn.fm/cO5VE).

The company recently completed a firm commitment public offering of 806,452 shares of its common stock following a voter-approved reverse stock split. Trxade expects to gain gross proceeds of $5.2 million from the sale of common stock in the offering, minus standard expenses tied to the offering.

Trxade Group relishes its role as a health care industry influencer intent on enabling price transparency and increased profit margins to health care buyers and sellers of pharmaceuticals, particularly the nation’s independent pharmacies that serve small, close-knit communities.

The company anticipates using the net proceeds of the public offering for its own general corporate purposes and possibly to fund acquisitions of other companies, products or technologies – part of Trxade’s strategy for increasing shareholder value and advancing its business model.

Trxade’s network of platform clients includes nearly 11,900 independent pharmacies registered and the company aims to continuously grow the size of the network until most, if not all, of the nation’s 24,000 independent pharmacies are represented with a combined annual purchasing power of more than $92 billion to help them compete with larger pharmaceutical companies.

“During the third quarter of 2019, we made excellent progress in our core proprietary B2B trading platform www.trxade.com, which enables independent pharmacies to purchase drugs at discount prices compared to their primaries, enabling us to experience top and bottom line growth,” Ajjarapu stated (http://ibn.fm/Yau0t). “Additionally, we are investing in core infrastructure for our B-to-C (Community Specialty Pharmacy) business in our wholesale, e-commerce and delivery capabilities as increasing pharmaceutical prices drive independent pharmacies, payors and consumers to be more aggressive in sourcing medication.”

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIR

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

MissionIRNewsBreaks – Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Announces Comprehensive Upgrade of System for Evaluating Children

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a producer, developer and operator of augmented reality (“AR”) interactive entertainment games, toys and educational materials in China, today announced a comprehensive upgrade of its system for evaluating children’s ability in an educational context. Per the update, the system, a central component of Blue Hat’s smart immersive educational products, is expected to be officially put into use after the beginning of the 2020 preschool spring semester in China. “Blue Hat’s innovative system for evaluating the developmental progress of preschool students is an essential component of our recently launched smart immersive educational suite of products. We believe that this update will improve our ability to obtain additional partnerships with preschools in China,” Blue Hat CEO Xiaodong Chen said in the news release. “In the future, Blue Hat expects to continue to tap the potential of big data, launch more targeted educational products, and help children develop to their full potential. We believe the rapid development of China’s 5G infrastructure will be a significant driver in this product’s future success.”

To view the full press release, visit http://ibn.fm/R48Ks

About Blue Hat

Blue Hat Interactive Entertainment Technology is a producer, developer and operator of AR interactive entertainment games and toys in China, including interactive educational materials, mobile games, and toys with mobile game features. The company’s interactive entertainment platform creates unique user experiences by connecting physical items to mobile devices, which creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. Distinguished by its own proprietary technology, Blue Hat aims to create an engaging, interactive and immersive community for its users. For more information, visit the company’s website at www.BlueHatGroup.net.

NOTE TO INVESTORS: The latest news and updates relating to BHAT are available in the company’s newsroom at http://ibn.fm/BHAT

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Wednesday, February 26, 2020

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Employs Unique Cancer-Research Approach

Predictive Oncology’s (NASDAQ: POAI) flagship subsidiary TumorGenesis is making strides in the identification and separation of cancer-related biomarkers in an effort to quicken the development of new, effective therapeutics. TumorGenesis is currently utilizing a new trend in cancer research that leverages patient-derived xenografts (“PDx”). A recent article discussing the company reads, “Science has shifted to these much more accurate PDx models: A cancer patient’s tumor cells are implanted into an alternate environment to simulate the natural development of the tumor. By ‘fooling the tumor’ with an imitative environment, new drugs are able to be tested and potentially approved — all without subjecting cancer patients to aggressive, potentially ineffective drugs. The cancer cells are tricked into thinking they’re still multiplying inside the patient, which makes the tumor behave as it would normally — revealing more precise cancer biomarkers. TumorGenesis’ unique research approach benefits from the parent company’s enormous database of tumor drug-response profiles and artificial intelligence-driven predictive modeling capabilities. . . . TumorGenesis has developed its proprietary methodology using PDx to culture tumor cells in vivo (i.e. in living organisms). These cell models can be then tested repeatedly for various new drugs to establish personalized therapeutics. This patient-specific data is revolutionizing the way cancer is treated today, and POAI, through its strategic subsidiary arms, poses an attractive option for investors looking to invest in the cancer treatment of tomorrow.”

To view the full article, visit http://ibn.fm/eFafn

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through five segments (domestic, international, clinical, CRO and D-CHIP), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient-treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision-oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (“D-CHIP”) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Sigma Labs Inc. (NASDAQ: SGLB) Offers ‘Singular Solution’ in Growing Aerospace 3D-Metal-Printing Market

Aerospace 3D-printing market forecast to reach more than $3 billion in 2022
Industry expert calls in-process quality control “one of the most promising developments in metal ALM production”
SGLB technology represents paradigm shift in quality-control process for manufacturing of 3D-printed metal components

The additive marketing, or 3D printing, industry is flying high in the aerospace sector. A Research and Markets study reported the aerospace 3D printing market is expected to grow from $714.5 million in 2017 to $3,057.9 billion by 2022 — a CAGR of 27.42% (http://ibn.fm/ly23w). Those numbers could go even higher as quality-assurance obstacles that have impeded the full adoption of 3D metal printing are successfully eliminated by Sigma Labs Inc. (NASDAQ: SGLB), the only provider of in-process, quality-assurance software to the commercial 3D-metal- printing industry.

“Aerospace has a long history of latest technology inventions’ early adopter and ultimate trendsetter in manufacturing,” according to an article by Farinia Group – a manufacturing organization dedicated to material transformation using state-of-the art equipment, know-how and technical expertise (http://ibn.fm/qeUsL). “New materials, state-of-the-art manufacturing processes and sophisticated software were created and absorbed by this industry decades ago and are now common for other industries.”

The Farinia Group noted several advantages of 3D printing in the aerospace sector, including the following:

Shorter development process and time to market
Freedom to design complex geometries, leading to maximized performance, consolidated design, improved reliability, and improved fuel efficiency
On-demand and on-site spares manufacturing
Higher material efficiency
Reduced costs for certain components
In-process quality assurance reducing overall lead time

It is in this last area – in-process quality assurance – where Sigma Labs shines. The company’s proprietary PrintRite3D® software is the singular solution that enables real-time, in-process detection of manufacturing irregularities for critical metal parts. The technology then provides the operator with the information and ability to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality-control process for the manufacture of 3D printed metal components. The company is the only provider of in-process quality-assurance software to the commercial 3D-metal-printing industry offering these capabilities.

“Aerospace, as an industry obsessed by performance and reliability, has since long performed quality-assurance downstream to manufacturing,” the Farinia Group article continues. “A critical stage for aerospace manufacturers in which any serial production often have to meet high specifications to satisfy stringent applications with high quality to ensure reliability. Insomuch that quality assurance can account significantly in the overall lead time and overall cost.”

In its report, the Farinia Group noted that “one of the most promising developments in metal ALM (additive layer manufacturing) production systems concerns the real-time and closed-loop in-process quality control…Monitoring the system settings and process parameters during the ongoing manufacturing permits to regulate and optimize conditions… In-process inspection of the material health and dimensional accuracy will surely unlock the power of ALM technology for serial aerospace production as qualification and consistency variation are now the main concerns.”

Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided-inspection (CAI) solutions known as PrintRite3D for 3D advanced manufacturing technologies. SGLB’s advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production – uniquely allowing errors to be corrected in real time.

For more information about Sigma Labs, please visit www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIR

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

MissionIRNewsBreaks – Sigma Labs, Inc. (NASDAQ: SGLB) Awarded Contract by Leading Research Institution Mississippi State University Center for Advanced Vehicular Systems

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, today announced that it has been awarded a contract by the Mississippi State University Center for Advanced Vehicular Systems (“CAVS”), a world-class interdisciplinary research center that uses state-of-the-art technology to address engineering challenges facing U.S. mobility industries. Per the update, CAVS will install PrinteRite3D on a Renishaw AM400 machine, a new OEM platform for Sigma Labs, further proving the interoperability potential of PrintRite3D’s platform to an increasingly large machine base. Under the agreement, in addition to any PrintRite3D(R) research or commercial applications, CAVS has agreed to serve as a real-world test bed for new product improvements that Sigma will deploy over time. “The Research & Development and University sectors of the additive manufacturing (“AM”) market is important to Sigma as we expand our footprint in the retail market segment with another contract win with the Mississippi State University Center for Advanced Vehicular Systems, a leading research institution and thought leader,” Sigma Labs Executive Chairman Mark K. Ruport said in the news release. “They have agreed to act as a test bed for new product improvements to PrintRite3D(R), uniquely allowing us a real-world feedback loop to continuously improve our technology suite. I look forward to working with the entire team at CAVS to bring a new level of quality assurance to both their partners and the additive manufacturing industry as a whole.”

To view the full press release, visit http://ibn.fm/jFSBq

About Sigma Labs

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Tuesday, February 25, 2020

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enhances Cannabis Products’ Shelf-Life Potency, Addressing Industry Distribution Challenges

Many cannabis companies have struggled with declining investor interest amid product delivery shortfalls and adverse revenue reports
The distribution obstacles have exacerbated company concerns by creating choking points for inventory, which can quickly lose potency in storage
Lexaria Bioscience’s trademarked DehydraTECH powder-creating technology helps preserve cannabinoid effectiveness and extend storage potential 2 to 3 years
The DehydraTECH platform also provides a key benefit in making cannabinoids, nicotine, NSAIDs and other drug products bioavailable as rapidly as inhaled products
An alternative to inhaled smokes and vapes could provide health and wellness benefits to consumers by eliminating harm to users’ lungs
Lexaria’s licensing strategy also enables other companies to utilize DehydraTECH’s IP in their products

As the cannabis industry works to weather 2019’s adverse profit and productivity reports (http://ibn.fm/niYkO), consumption drug platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is helping to ensure that product inventories can remain potent and perform at their potential despite a natural tendency for cannabinoids to deteriorate with time.

Public market investors have been short-term allies in a fledgling industry seeking long-term commitment, in large part because of initial sky-high expectations for profits from cannabis-related industries and regulatory hurdles from government oversight of a once-illegal product that have kept the brakes on runaway commerce. As a result, many companies have built up outsized debt-revenue ratios (http://ibn.fm/G29Ig).

Added to those concerns, a European study determined that the potency of tetrahydrocannabinol (THC) and cannabidiol (CBD) tends to degrade over time – THC by 20 percent per year while in storage and CBD by 10 percent (http://ibn.fm/3Dj6d), ensuring a need for producers to get their products to market in a timely fashion. Additionally, a study of storage mediums used for THC found that certain types of packaging can contribute to the degradation of the extract’s potency (http://ibn.fm/w0INv).

The adverse factors have combined to create a potential source of caution among consumers as some companies have had to report multi-million-dollar losses due to “congested inventory channels” resulting from production that has exceeded sales (http://ibn.fm/gbogP).

Lexaria’s product-stabilizing DehydraTECH(TM) oral drug delivery IP turns cannabis and hemp oils into powders that preserve the cannabinoid extracts in the products while mitigating microbiological growth to help the products last longer on retail shelves – the company reports (http://ibn.fm/KEyQ4) that products can be stored for two to three years and experience “reduced loss of cannabinoids compared to current industry practices.”

DehydraTECH’s primary benefit is that it enables swallowed drug substances to deliver their intended effects as rapidly and effectively as inhaled products such as smokes or vapes. Many consumers continue to prefer inhaling products containing nicotine-rich tobacco or cannabis-based marijuana and CBD, acknowledging that they get a quicker, better response than if they try to use other medicinal/wellness delivery methods.

The dangers of inhaling drug substances into the lungs have been established over decades, with recent concerns about vape ingredients adding new fuel to the fire (http://ibn.fm/ncC40). Lexaria is committed to combatting the deleterious effects of drug inhalation by making swallowed drug products more rapidly bioavailable in the bloodstream, and thereby as attractive as inhaled products if not more so.

In addition to the DehydraTECH products Lexaria markets, the company also licenses its technology to other companies for them to use in all of their edible and topical cannabis and/or hemp extract processing needs. Lexaria is able to process 250,000 servings of CBD at 10 mg each per day currently for distribution across the country.

Although CBD-based wellness products continue to remain under scrutiny by the federal government, many states have legalized topical and edible uses. A recent licensing agreement between Lexaria and the smokeless Cannadips CBD brand is drawing on DehydraTECH’s IP for a product chain available nationally through Circle K convenience outlets, in about 5,000 stores throughout the United States.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIR

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

MissionIRNewsBreaks – Youngevity International Inc.’s (NASDAQ: YGYI) CLR Roasters Forges New Distribution Partnership with Prestigious Distributor Krasdale Foods

Youngevity International (NASDAQ: YGYI), a multi-channel lifestyle company operating in three distinct business segments, today announced that its wholly-owned subsidiary CLR Roasters has forged a new distribution partnership with prestigious distributor Krasdale Foods. In the business for over 100 years, Krasdale Foods distributes over 12,000 grocery item SKUs, services over 2500 retail locations and its geographic footprint includes NYC and metro areas in New York, as well as New Jersey, Connecticut, Pennsylvania, Massachusetts, and Rhode Island. Krasdale Foods plans to begin distribution of Café La Rica next month, with, in the first week of March, an initial stocking order of Café La Rica’s gourmet espresso shipping from CLR Roasters to Krasdale’s Bronx, NY-based distribution facility. “We are proud to see CLR’s Flagship brand, Café La Rica, pick up such a significant and prestigious distribution partner” Youngevity President and CFO Dave Briskie said in the news release. “We expect the continuation of this partnership to help drive the continued growth of our Café La Rica brand throughout 2020.”

To view the full press release, visit http://ibn.fm/NA8Oo

About Youngevity International

Youngevity International, Inc. (NASDAQ : YGYI ) is an multi-channel lifestyle company operating in three distinct business segments including a commercial coffee enterprise, a commercial hemp enterprise, and a multi-vertical omni direct selling enterprise. The Company features a multi country selling network and has assembled a virtual Main Street of products and services under one corporate entity, YGYI offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. For investor information, please visit www.YGYI.com.

NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://ibn.fm/YGYI

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

MissionIRNewsBreaks – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) Announces Q2 Fiscal 2020 Results

Green Growth Brands (CSE: GGB) (OTCQB: GGBXF) on Monday released its results for the period ended December 28, 2019. According to the update, Green Growth Brands’ revenues for the period totaled $21.1M. “The results this quarter are a reflection of our ability to create products and experiences that consumers want,” Green Growth Brands CEO Peter Horvath said in the news release. “We are pleased with the consumer demand signals we saw in the CBD segment during the quarter, and we remain confident in its future potential. However, overhead costs, near-term obligations and constraints on liquidity have posed significant challenges that have hindered us from growing the CBD business in the timeframes we anticipated to its full-potential. The initiatives we announced today to sell the CBD segment, restructure debt and raise equity financing improves the financial infrastructure we need to scale our MSO segment. We believe focusing our expertise on the MSO segment will yield the highest long-term value for our shareholders and customers.”

To view the full press release, visit http://ibn.fm/oAbQO

About Green Growth Brands Inc.

Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and 8 Fold. The Company also has a licensing agreement with the Greg Norman(TM) Brand to develop a line of CBD-infused personal care products designed for active wellness. GGB is expanding its cannabis operations throughout the U.S., via dispensaries in Nevada, Massachusetts and Florida and the largest network of CBD shops in malls across the country and ShopSeventhSense.com. Learn more about the vision at GreenGrowthBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to GGBXF are available in the company’s newsroom at http://ibn.fm/GGBXF

About MissionIRNewsBreaks

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Monday, February 24, 2020

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Selects Manufacturer, Distributor of Innovative Cell-Culture Media

POAI subsidiary announces new media for growing ovarian tumors in lab
Using new product, TumorGenesis partners have identified 25 cell types from ovarian cancers
New media available as cell-culture market expected to reach $2.3 billion by 2024

Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, along with its subsidiary TumorGenesis Inc., has announced an innovative special media for growing ovarian tumors; the companies have also selected US Biological Corporation as a manufacturer and distributor of the groundbreaking media (http://ibn.fm/QjW3K). POAI anticipates the new formulations, which will be developed in a lab, will speed discovery of biomarkers and precision therapies.

“Using these proprietary media, our partners have identified 25 cell types from ovarian tumors, which to a large degree have never been screened or studied by researchers,” TumorGenesis President Richard Gabriel stated in a news release. “The resulting cells have a 95+% match to cells found in patient bodies.”

The timing of POAI’s announcement couldn’t be better. Experts predict that the global cell-culture media market will reach $2.3 billion by 2024. That growth – a steady 8.4% CAGR – is primarily fueled by the increased use of biological-based drugs such as immune therapies, a space where POAI and its subsidiaries are establishing themselves as both leaders and pioneers.

POAI anticipates that the new media will be available Q1 2020 through Massachusetts-based US Biological, a primary brand for the life-science industry. United States Biological’s biochemicals, antibodies, recombinant proteins, cell-culture media and molecular biology kits are used in virtually all scientific applications and settings including genomic research, biotechnology, pharmaceutical development and the diagnosis of disease.

Traditionally, cell-culture media selects for only one or two fast-growing cell types, so the ability to identify 25 different cell types is a significant advancement. The proprietary media developed by TumorGenesis are designed specifically to assist researchers in isolating and maintaining the unique histological and basic biological signatures of heterogeneous ovarian cell types while growing them in the laboratory.

“We believe by helping researchers develop cells and tumors that more closely mimic cells and tumors found in patient bodies, we can help lower the cost and speed the discovery of drugs and therapies that will approve patient outcomes,” said Gabriel. Acknowledging that specialty media comprises only a small subset of the market, Gabriel explained that TumorGenesis sees this initial ovarian-specific formulation as the first in what the company anticipates being a long line of tools and services it will offer to cancer researchers.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug repose to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIR

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com